Prognostic impact of clinical variables on surgically resected small-cell lung cancer

Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A)

Hiroshi Yokouchi, Takashi Ishida, Shigeo Yamazaki, Hajime Kikuchi, Satoshi Oizumi, Hidetaka Uramoto, Fumihiro Tanaka, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Tatsuro Fukuhara, Kei Takamura, Tetsuya Kojima, Toshiyuki Harada, Mitsunori Higuchi, Yoshifumi Matsuura, Osamu Honjo, Yoshinori Minami, Naomi Watanabe & 6 others Hiroshi Nishihara, Hiroyuki Suzuki, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura, Mitsuru Munakata

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives: Several American and Japanese guidelines recommend surgery for patients with c-stage I small-cell lung cancer (SCLC), whereas the European Society of Medical Oncology (ESMO) guidelines recommend surgery for patients with not only c-stage I but also c-stage II (T2N1) SCLC. In addition, previous studies identified various factors other than clinical stage that are related to survival in these patients. Thus, further validation and examination of the association of clinical stage and other clinical variables with survival are required for establishing practical management of early-stage SCLC. Patients and methods: We reviewed the clinical courses of 156 SCLC patients who had undergone surgery at 17 institutions between January 2003 and January 2013. Results: Clinical stages (tumor-node-metastasis [TNM] version 7) of the 156 patients were 98 cases in IA, 14 in IB, 16 in IIA, 7 in IIB, 18 in IIIA, and 3 in IIIB. Median overall survival (OS) was 33.3 months (95% confidence interval: 20.9-45.8). Multivariate analysis revealed that OS was longer in patients either at c-stage II and under, with a maximum tumor diameter of <20 mm, with preoperative diagnosis, without a history or presence of other types of cancer, or who underwent prophylactic cranial irradiation (PCI). Conclusion: These results indicate that a history or presence of other types of cancer might be a major decisive factor for surgery. Patients with c-stages I and II (c-T2N1) can be considered for surgery, and PCI may be useful in patients undergoing surgery in a practical setting, partly supporting the ESMO guidelines.

Original languageEnglish
Pages (from-to)548-553
Number of pages6
JournalLung Cancer
Volume90
Issue number3
DOIs
Publication statusPublished - 2015 Dec 1
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Cranial Irradiation
Survival
Medical Oncology
Guidelines
Neoplasms
History
Multivariate Analysis
Confidence Intervals
Neoplasm Metastasis

Keywords

  • C-Stage II
  • Preoperative diagnosis
  • Prophylactic cranial irradiation
  • Small-cell lung cancer
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Prognostic impact of clinical variables on surgically resected small-cell lung cancer : Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A). / Yokouchi, Hiroshi; Ishida, Takashi; Yamazaki, Shigeo; Kikuchi, Hajime; Oizumi, Satoshi; Uramoto, Hidetaka; Tanaka, Fumihiro; Harada, Masao; Akie, Kenji; Sugaya, Fumiko; Fujita, Yuka; Fukuhara, Tatsuro; Takamura, Kei; Kojima, Tetsuya; Harada, Toshiyuki; Higuchi, Mitsunori; Matsuura, Yoshifumi; Honjo, Osamu; Minami, Yoshinori; Watanabe, Naomi; Nishihara, Hiroshi; Suzuki, Hiroyuki; Dosaka-Akita, Hirotoshi; Isobe, Hiroshi; Nishimura, Masaharu; Munakata, Mitsuru.

In: Lung Cancer, Vol. 90, No. 3, 01.12.2015, p. 548-553.

Research output: Contribution to journalArticle

Yokouchi, H, Ishida, T, Yamazaki, S, Kikuchi, H, Oizumi, S, Uramoto, H, Tanaka, F, Harada, M, Akie, K, Sugaya, F, Fujita, Y, Fukuhara, T, Takamura, K, Kojima, T, Harada, T, Higuchi, M, Matsuura, Y, Honjo, O, Minami, Y, Watanabe, N, Nishihara, H, Suzuki, H, Dosaka-Akita, H, Isobe, H, Nishimura, M & Munakata, M 2015, 'Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A)', Lung Cancer, vol. 90, no. 3, pp. 548-553. https://doi.org/10.1016/j.lungcan.2015.10.010
Yokouchi, Hiroshi ; Ishida, Takashi ; Yamazaki, Shigeo ; Kikuchi, Hajime ; Oizumi, Satoshi ; Uramoto, Hidetaka ; Tanaka, Fumihiro ; Harada, Masao ; Akie, Kenji ; Sugaya, Fumiko ; Fujita, Yuka ; Fukuhara, Tatsuro ; Takamura, Kei ; Kojima, Tetsuya ; Harada, Toshiyuki ; Higuchi, Mitsunori ; Matsuura, Yoshifumi ; Honjo, Osamu ; Minami, Yoshinori ; Watanabe, Naomi ; Nishihara, Hiroshi ; Suzuki, Hiroyuki ; Dosaka-Akita, Hirotoshi ; Isobe, Hiroshi ; Nishimura, Masaharu ; Munakata, Mitsuru. / Prognostic impact of clinical variables on surgically resected small-cell lung cancer : Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A). In: Lung Cancer. 2015 ; Vol. 90, No. 3. pp. 548-553.
@article{76db349de6a649af875d52db52f5d46b,
title = "Prognostic impact of clinical variables on surgically resected small-cell lung cancer: Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A)",
abstract = "Objectives: Several American and Japanese guidelines recommend surgery for patients with c-stage I small-cell lung cancer (SCLC), whereas the European Society of Medical Oncology (ESMO) guidelines recommend surgery for patients with not only c-stage I but also c-stage II (T2N1) SCLC. In addition, previous studies identified various factors other than clinical stage that are related to survival in these patients. Thus, further validation and examination of the association of clinical stage and other clinical variables with survival are required for establishing practical management of early-stage SCLC. Patients and methods: We reviewed the clinical courses of 156 SCLC patients who had undergone surgery at 17 institutions between January 2003 and January 2013. Results: Clinical stages (tumor-node-metastasis [TNM] version 7) of the 156 patients were 98 cases in IA, 14 in IB, 16 in IIA, 7 in IIB, 18 in IIIA, and 3 in IIIB. Median overall survival (OS) was 33.3 months (95{\%} confidence interval: 20.9-45.8). Multivariate analysis revealed that OS was longer in patients either at c-stage II and under, with a maximum tumor diameter of <20 mm, with preoperative diagnosis, without a history or presence of other types of cancer, or who underwent prophylactic cranial irradiation (PCI). Conclusion: These results indicate that a history or presence of other types of cancer might be a major decisive factor for surgery. Patients with c-stages I and II (c-T2N1) can be considered for surgery, and PCI may be useful in patients undergoing surgery in a practical setting, partly supporting the ESMO guidelines.",
keywords = "C-Stage II, Preoperative diagnosis, Prophylactic cranial irradiation, Small-cell lung cancer, Surgery",
author = "Hiroshi Yokouchi and Takashi Ishida and Shigeo Yamazaki and Hajime Kikuchi and Satoshi Oizumi and Hidetaka Uramoto and Fumihiro Tanaka and Masao Harada and Kenji Akie and Fumiko Sugaya and Yuka Fujita and Tatsuro Fukuhara and Kei Takamura and Tetsuya Kojima and Toshiyuki Harada and Mitsunori Higuchi and Yoshifumi Matsuura and Osamu Honjo and Yoshinori Minami and Naomi Watanabe and Hiroshi Nishihara and Hiroyuki Suzuki and Hirotoshi Dosaka-Akita and Hiroshi Isobe and Masaharu Nishimura and Mitsuru Munakata",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.lungcan.2015.10.010",
language = "English",
volume = "90",
pages = "548--553",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Prognostic impact of clinical variables on surgically resected small-cell lung cancer

T2 - Results of a retrospective multicenter analysis (FIGHT002A and HOT1301A)

AU - Yokouchi, Hiroshi

AU - Ishida, Takashi

AU - Yamazaki, Shigeo

AU - Kikuchi, Hajime

AU - Oizumi, Satoshi

AU - Uramoto, Hidetaka

AU - Tanaka, Fumihiro

AU - Harada, Masao

AU - Akie, Kenji

AU - Sugaya, Fumiko

AU - Fujita, Yuka

AU - Fukuhara, Tatsuro

AU - Takamura, Kei

AU - Kojima, Tetsuya

AU - Harada, Toshiyuki

AU - Higuchi, Mitsunori

AU - Matsuura, Yoshifumi

AU - Honjo, Osamu

AU - Minami, Yoshinori

AU - Watanabe, Naomi

AU - Nishihara, Hiroshi

AU - Suzuki, Hiroyuki

AU - Dosaka-Akita, Hirotoshi

AU - Isobe, Hiroshi

AU - Nishimura, Masaharu

AU - Munakata, Mitsuru

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives: Several American and Japanese guidelines recommend surgery for patients with c-stage I small-cell lung cancer (SCLC), whereas the European Society of Medical Oncology (ESMO) guidelines recommend surgery for patients with not only c-stage I but also c-stage II (T2N1) SCLC. In addition, previous studies identified various factors other than clinical stage that are related to survival in these patients. Thus, further validation and examination of the association of clinical stage and other clinical variables with survival are required for establishing practical management of early-stage SCLC. Patients and methods: We reviewed the clinical courses of 156 SCLC patients who had undergone surgery at 17 institutions between January 2003 and January 2013. Results: Clinical stages (tumor-node-metastasis [TNM] version 7) of the 156 patients were 98 cases in IA, 14 in IB, 16 in IIA, 7 in IIB, 18 in IIIA, and 3 in IIIB. Median overall survival (OS) was 33.3 months (95% confidence interval: 20.9-45.8). Multivariate analysis revealed that OS was longer in patients either at c-stage II and under, with a maximum tumor diameter of <20 mm, with preoperative diagnosis, without a history or presence of other types of cancer, or who underwent prophylactic cranial irradiation (PCI). Conclusion: These results indicate that a history or presence of other types of cancer might be a major decisive factor for surgery. Patients with c-stages I and II (c-T2N1) can be considered for surgery, and PCI may be useful in patients undergoing surgery in a practical setting, partly supporting the ESMO guidelines.

AB - Objectives: Several American and Japanese guidelines recommend surgery for patients with c-stage I small-cell lung cancer (SCLC), whereas the European Society of Medical Oncology (ESMO) guidelines recommend surgery for patients with not only c-stage I but also c-stage II (T2N1) SCLC. In addition, previous studies identified various factors other than clinical stage that are related to survival in these patients. Thus, further validation and examination of the association of clinical stage and other clinical variables with survival are required for establishing practical management of early-stage SCLC. Patients and methods: We reviewed the clinical courses of 156 SCLC patients who had undergone surgery at 17 institutions between January 2003 and January 2013. Results: Clinical stages (tumor-node-metastasis [TNM] version 7) of the 156 patients were 98 cases in IA, 14 in IB, 16 in IIA, 7 in IIB, 18 in IIIA, and 3 in IIIB. Median overall survival (OS) was 33.3 months (95% confidence interval: 20.9-45.8). Multivariate analysis revealed that OS was longer in patients either at c-stage II and under, with a maximum tumor diameter of <20 mm, with preoperative diagnosis, without a history or presence of other types of cancer, or who underwent prophylactic cranial irradiation (PCI). Conclusion: These results indicate that a history or presence of other types of cancer might be a major decisive factor for surgery. Patients with c-stages I and II (c-T2N1) can be considered for surgery, and PCI may be useful in patients undergoing surgery in a practical setting, partly supporting the ESMO guidelines.

KW - C-Stage II

KW - Preoperative diagnosis

KW - Prophylactic cranial irradiation

KW - Small-cell lung cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84949212361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949212361&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2015.10.010

DO - 10.1016/j.lungcan.2015.10.010

M3 - Article

VL - 90

SP - 548

EP - 553

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -